Jefferies Maintains a 'Buy' on Cyberonics (CYBX); First Depression Paper Released
Get Alerts CYBX Hot Sheet
Price: $69.95 --0%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Cyberonics (NASDAQ: CYBX) price target of $58.00.
Analyst, Raj Denhoy, said, "Results from the analysis of outcomes of VNS therapy for treatment-resistant depression in Medicare patients were released in manuscript form ahead of publication in the upcoming Journal of Medical Economics. The analysis reads quite favorably for VNS and could be instrumental in reconsideration of coverage for TRD by CMS and private payors."
For an analyst ratings summary and ratings history on Cyberonics click here. For more ratings news on Cyberonics click here.
Shares of Cyberonics closed at $50.13 yesterday.
Analyst, Raj Denhoy, said, "Results from the analysis of outcomes of VNS therapy for treatment-resistant depression in Medicare patients were released in manuscript form ahead of publication in the upcoming Journal of Medical Economics. The analysis reads quite favorably for VNS and could be instrumental in reconsideration of coverage for TRD by CMS and private payors."
For an analyst ratings summary and ratings history on Cyberonics click here. For more ratings news on Cyberonics click here.
Shares of Cyberonics closed at $50.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share